HemaCare Achieves Q2 Conference Goals

HemaCare Corporation,(OTCBB:HEMA) a leader in cell and tissue collection, processing, and cell therapy solutions, today announced that it achieved its Q2 marketing goals of driving greater awareness of its capabilities to potential new customers, as well as maintaining and developing deeper collaborations with current customers and partners. At the American Association for Cancer Research meeting in April, HemaCare delivered a record number of new customer signups for inclusion in its email channel with researchers and developers of diagnostics and cancer therapies. At the International Society of Cell Therapy annual meeting in May, HemaCare shared in the ongoing collaborations with a very global group of attendees focused on delivering life-changing cell therapies. At Bio2016 in early June, HemaCare identified multiple new collaborations for global distribution and partnerships to broaden its reach wherever investigators need human hematopoietic cells. And later in June, at the International Society for Stem Cell Research, HemaCare met many new potential customers in need of precious stem cells for the study and development of innovative treatments using stem cells derived from bone marrow and cord blood sources.

HemaCare is the recognized apheresis leader in supporting autologous and allogeneic cell therapy, as well as supplying a broad array of hematopoietic tissue –derived cells for research, including bone marrow and umbilical cord blood. What sets us apart from others is our heritage as a transfusable collection center with over 38 years of experience operating an FDA registered, cGMP/cGTP compliant donor center. HemaCare manages hundreds of reliable & recallable donors, who can meet various criteria for selection to be used for allogeneic cell therapy starting material globally.

“We will continue to support and attend key scientific and clinical conferences to ensure broad global awareness of our capabilities to deliver HemaCare’s portfolio of human primary hematopoietic cells, a necessary component for these researchers to develop and implement innovative treatments and cures for diseases where the body’s own immune system can be programmed to fight the disease,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “We understand the critical need researchers have for our products and specialized capabilities and will continue to dedicate our business to aid in the pursuit of these treatments.”

View our product story at www.hemacare.com,

About HemaCare

Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 38-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. HemaCare’s expertise extends to serving biopharmaceutical firms with autologous and allogeneic collections used for Cell Therapy research, process development, and clinical trials. For more information please visit www.hemacare.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160711005013/en/